1-2020

Continuous-flow left ventricular assist device outflow graft stenting: Indications and outcomes

Chelsey T. Wood, MFA
*Thomas Jefferson University, chelsey.wood@jefferson.edu*

Elizabeth J. Maynes, MD
*Thomas Jefferson University, elizabeth.maynes@jefferson.edu*

Thomas J. O’Malley, MD
*Thomas Jefferson University, thomas.o'malley2@jefferson.edu*

Rohinton J. Morris, MD
*Thomas Jefferson University, rohinton.j.morris@jefferson.edu*

Louis E. Samuels, MD
*Thomas Jefferson University, louis.samuels@jefferson.edu*

Follow this and additional works at: [https://jdc.jefferson.edu/si_ctr_2022_phase1](https://jdc.jefferson.edu/si_ctr_2022_phase1)

*Part of the Cardiology Commons, Surgery Commons, and the Translational Medical Research Commons*

**Let us know how access to this document benefits you**

See next page for additional authors

**Recommended Citation**

Wood, MFA, Chelsey T.; Maynes, MD, Elizabeth J.; O’Malley, MD, Thomas J.; Morris, MD, Rohinton J.; Samuels, MD, Louis E.; Massey, MD, H. Todd; and Tchantchaleishvili, Vakhtang, "Continuous-flow left ventricular assist device outflow graft stenting: Indications and outcomes" (2020).

*Phase 1. Paper 5.*

[https://jdc.jefferson.edu/si_ctr_2022_phase1/5](https://jdc.jefferson.edu/si_ctr_2022_phase1/5)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Chelsey T. Wood, MFA; Elizabeth J. Maynes, MD; Thomas J. O'Malley, MD; Rohinton J. Morris, MD; Louis E. Samuels, MD; H. Todd Massey, MD; and Vakhtang Tchantchaleishvili

This abstract is available at Jefferson Digital Commons: https://jdc.jefferson.edu/si_ctr_2022_phase1/5
Continuous-flow left ventricular assist device outflow graft stenting: Indications and outcomes


Introduction: Stenosis in the continuous-flow left ventricular assist device (CF-LVAD) outflow graft can be caused by various mechanical and anatomical factors. Increasingly, percutaneous management has been utilized to re-establish adequate CF-LVAD flow. We sought to evaluate indications for such interventions and their outcomes.

Methods: An electronic search was performed to identify all studies in the English literature reporting CF-LVAD outflow graft stenting for various etiologies. Twenty-one studies consisting of 26 patients were included in the analysis.

Results: Median patient age was 59 years [45.8-67.0] and 65.4% (17/26) were male. 58.3% (14/24) of patients had HeartWare HVAD, 37.5% (9/24) had HeartMate II LVAD, and 4.2% (1/24) had HeartMate III LVAS. Median time from device placement to outflow graft stenting was 24.0 months [7.8-30.4]. 76.9% of patients (20/26) presented with heart failure. 34.6% (9/26) had outflow graft thrombosis, 34.6% (9/26) stenosis, 11.5% (3/26) kinking, 11.5% (3/26) pseudoaneurysm, 3.8% (1/26) external graft compression, and 3.8% (1/26) had a bronchial-arterial fistula. 88.5% (23/26) procedures led to immediate flow improvement with the remaining 11.5% (3/26) receiving additional stenting. Post-intervention flows were significantly improved (4.7 L/min [4.1-4.8] post-intervention vs 2.9 L/min [2.0-3.5] initial, p=0.01). 96.2% (25/26)
patients were discharged from the hospital. The 30-day mortality was 6.7% (1/15). Overall mortality during the median follow-up of 90 days [7.0-240.0] was 9.5% (2/21).

**Discussion:** Outflow graft stenting appears to effectively alleviate CF-LVAD outflow graft obstruction with low mortality. Longer-term follow up is necessary to determine the longevity of such an intervention but early results are promising.